Biogen sues Teva over MS generic

A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity (diroximel fumarate), according to a lawsuit filed by Biogen and Alkermes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

English High Court finds Bayer patent obvious in win for Teva

11 October 2021 The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Americas

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

2 December 2021 The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.

Americas

Groups urge Fed Circ to rehear Biogen patent case

18 January 2022 Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.